QuidelOrtho Balances Near-Term Strain With Recovery Plan

Quidelortho Corporation ((QDEL)) has held its Q1 earnings call. Read on for the main highlights of the call.

QuidelOrtho’s latest earnings call painted a cautious but constructive picture as the company works through a weak respiratory season, China uncertainty, and near‑term margin pressure while leaning on new products, cost cuts, and a recently closed acquisition. Management balanced frank discussion of current setbacks with confidence in a path to margin recovery and positive free cash flow this year.

Lex Diagnostics Deal Brings Ultrafast Molecular Platform

QuidelOrtho closed its acquisition of Lex Diagnostics, adding an ultrafast molecular point‑of‑care platform that management views as a future growth engine. Initial customer orders are in hand, with a few hundred instruments expected to be placed in 2026 and meaningful assay‑driven revenue anticipated from early 2027 as U.K. manufacturing capacity is expanded.

New Assays and Systems Target Labs Growth

The company highlighted strong commercial traction from its high‑sensitivity troponin assay, now shipping to more than 300 U.S. customers, alongside the rollout of the VITROS 450 system following CE Mark approval. These launches are aimed at boosting international lab growth across JAPAC, then LATAM and EMEA, and are expected to underpin mid‑single‑digit growth in the labs segment, which makes up more than half of total revenue.

Diversified Revenue Mix Offsets Respiratory Shortfall

In the quarter, QuidelOrtho generated $620 million in revenue, with non‑respiratory lines contributing $552 million and $544 million excluding donor screening. The mix underscores management’s emphasis that the business is no longer predominantly dependent on respiratory testing, even as the current season’s weakness weighs on headline results.

Immunohematology Delivers Steady Growth

Immunohematology continued to be a bright spot, posting 3% year‑over‑year revenue growth. Strength in North America, China, and JAPAC drove this performance, offering a measure of resilience in a quarter otherwise marked by soft demand in other diagnostics categories.

Cost Discipline Supports Margin Ambitions

Management underscored ongoing cost discipline, noting a 2% decline in non‑GAAP operating expenses, driven primarily by R&D efficiencies. The company has already eliminated about 1,000 positions and is pushing procurement savings, facility consolidation, including the Raritan shutdown, and targeted staff reductions to support future margin expansion.

Profitability Targets Despite Top‑Line Pressure

For the full year, QuidelOrtho is guiding to adjusted EBITDA of $615 million to $630 million, implying an approximate 23% margin and a 100‑basis‑point improvement over 2025. Adjusted diluted EPS is expected in a wide band of $0.80 to $2.00, reflecting both the near‑term earnings volatility and management’s confidence in longer‑term profitability.

Working Capital Gains and FX Tailwinds

The company reported strong working capital execution, with $54 million of accounts receivable collections in the quarter and a $22 million year‑over‑year reduction in capital expenditures. Foreign exchange provided an additional tailwind, lifting results by about 210 basis points in the quarter and partially offsetting operational headwinds.

Weak Respiratory Season Hits Revenue

A significantly weaker respiratory season was a central drag, with CDC data showing influenza‑like illness visits down roughly 30% in April versus the prior‑year quarter. Respiratory revenue dropped to $68 million, and management now models an 8% decline for the full year, assuming a flat second half as conditions stabilize but do not meaningfully rebound.

Labs Segment Faces Decline and Tough Comparisons

The labs business, more than half of total sales, fell 8% year‑over‑year in the first quarter, weighed down by softer demand and non‑recurring headwinds. The termination of a joint business agreement with Grifols also depressed comparisons, complicating the near‑term picture even as new assays and systems are rolled out to re‑ignite growth.

Gross Margin Compresses on Unfavorable Mix

Adjusted gross margin slipped to 44%, down 630 basis points from a year ago, primarily due to an adverse product mix as higher‑margin respiratory testing shrank. Management framed this pressure as cyclical rather than structural, expecting mix to improve as new platforms ramp and cost initiatives take hold over the medium term.

Quarterly Earnings Turn to Loss

Adjusted EBITDA for the quarter was $109 million, representing an 18% margin and a step down from prior periods. The company posted an adjusted diluted loss per share of $0.40, highlighting the intensity of near‑term profitability pressure as revenue softness and margin compression converge.

Cash Flow Headwinds and Higher Leverage

First‑quarter operating cash flow was negative $33 million, and free cash flow was negative $67 million, reflecting weaker earnings and the timing of investments. QuidelOrtho ended the quarter with $140 million in cash, $130 million drawn on its revolver, and net debt at 4.1 times adjusted EBITDA, with plans to bring leverage down to roughly 3.25 to 3.5 times by year‑end.

China Pricing Uncertainty Clouds Outlook

Sales in China slowed noticeably in March as distributors paused orders ahead of anticipated national IVD pricing guidelines, prompting a cut to the company’s revenue outlook. Management estimates about $30 million of the midpoint guidance reduction stems from China, noting that the draft pricing framework could affect roughly half of its sales in the country and potentially prolong uncertainty into 2027.

Macro and Geopolitics Delay Orders

Beyond China, broader macroeconomic and geopolitical tensions, including disruptions tied to the Middle East, contributed to order and tender delays. These factors weighed on first‑quarter performance and added timing risk to the recovery, even though management expects many of the orders to eventually come through rather than be lost outright.

Guidance Signals Soft First Half, Stronger Finish

Looking ahead, QuidelOrtho guided to full‑year 2026 revenue of $2.0 billion to $2.75 billion, along with adjusted EBITDA of $615 million to $630 million and free cash flow of $100 million to $120 million. Management expects second‑quarter results to be roughly in line with the first, with a stronger back half of the year needed to hit targets, even as they bake in an 8% respiratory revenue decline and about $75 million of total revenue headwinds from weaker respiratory demand and China.

QuidelOrtho’s call left investors weighing pronounced short‑term headwinds against clear steps toward long‑term improvement. If new platforms ramp as planned, cost actions stick, and respiratory testing and China stabilize, the company’s margin and cash flow story could improve materially, but execution against this plan will be closely watched in the coming quarters.